AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04794751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lens
Description: senofilcon A C3
Study NCT04794751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lens
Description: delefilcon A
Study NCT05874362 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diagnosis of depressive episode or post traumatic stress disorder
Description: Clinical diagnosis of depressive episode or post traumatic stress disorder, confirmed
Study NCT05874362 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No diagnosis of depressive episode or post traumatic stress disorder
Description: No elements in clinical assessment for the diagnosis of a depressive episode or post traumatic stress disorder
Study NCT05025592 — intervention group
Intervention type: DRUG
Intervention: Regorafenib
Description: patients will received TACE-HAIC and regorafenib and anti-PD1 antibody or not
Study NCT05025592 — intervention group
Intervention type: DEVICE
Intervention: cTACE/DEB-TACE-HAIC
Description: conventional transarterial chemoembolization(cTACE)/transarterial chemoembolization (DEB-TACE) plus hepatic artery infusion
Study NCT05512351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus Bevacizumab
Description: 200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
Study NCT05105334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonablative fractional laser (Fraxel re:store, Solta Medical, Bothell, WA) alone
Description: Nonablative fractional 1550 nm erbium:glass laser. Settings: 40-70 mJ, treatment level 5-7 (14-20% coverage), 8 passes with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. To be repeated for a total of 4 sessions at 4-week intervals.
Study NCT05105334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonablative fractional laser (Fraxel re:store, Solta Medical, Bothell, WA) alternating with microneedling with radiofrequency (Intracel, Perigee Medical, Redwood City, CA)
Description: Nonablative fractional 1550 nm erbium:glass laser. Settings: 40-70 mJ, treatment level 5-7 (14-20% coverage), 8 passes with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. This will be alternated with radiofrequency microneedling treatment will include 3 passes each at a depth of 2 mm, 1.5 mm, and 0.8 mm, treatment level 5 (32 w, 50 ms)-7 (40 w, 60 ms), monopolar setting with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. To be repeated for a total of 4 sessions (2 of each modality) at 4-week intervals.
Study NCT04934956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Split-belt walking
Description: These will be used in all experiments and consists of a time period during which the legs move at different speeds (0.5 m/s vs. 1 m/s). The investigators select those speeds since the investigators have observed in our preliminary data and published study (Sombric et al. 2017) that older individuals adapted at these speeds exhibit large deficits at motor switching when transitioning to overground walking. This large reference signal will facilitate the detection of a change in motor switching (Aim 2) following the Intervention.
Study NCT04934956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple transitions between split-belt and tied-belt walking
Description: This intervention consists of multiple short adaptation blocks (i.e., 6 blocks of 200 strides each) interleaved with short de-adaptation blocks (i.e., 5 blocks of 200 strides of tied-belt walking each). It was designed based on several studies showing improvements in adaptation rate in young adults with a similar protocol (Malone et al. 2011; Day et al. 2018; Leech et al. 2018).
Study NCT05817240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taladegib
Description: 100 mg per tablet, dosed once daily
Study NCT05817240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib
Description: 100 mg per capsule, dosed once daily
Study NCT04391543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental session
Description: * comprehensive interview~* cognitive tests~* anthropometric measures~* postural balance test~* critical force test~* Astrand-Ryhming test~* self-questionnaire (QLQ-C30, FA12, Brief Cope et Hospital Anxiety and Depression Scale)~* actimetry~* clinical and biological characteristics~* determination of inflammatory markers~* skeletal muscle index
Study NCT06142110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Funcional movement screen
Description: FMS is a biomechanical screening and evaluation method to reveal the limitations and asymmetries on the 7 basic movement patterns, which are the determinants of functional movement quality.
Study NCT06142110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle strength
Description: Respiratory muscle strength was assessed with an additional mouthpiece attached to the portable spirometer as maximum inspiratory pressure and maximum expiratory pressure.
Study NCT05359887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized liquid mixed meal Nutridrink®
Description: Administration of food in controlled situation
Study NCT06609655 — intervention group
Intervention type: OTHER
Intervention: no intervention studied, it&#39;s a databank
Description: The AgeTeQ database Arts, health and new information and communication technologies has three objectives.~The first is to preserve the data collected as part of the research projects carried out by the AgeTeQ laboratory.~The second objective of the database is to use the information provided by the recorded data to fuel reflection, test new research hypotheses and thus open up new avenues of research for the Arts, Health and New Information and Communication Technologies research team.~The third objective is to share the AgeTeQ database with the scientific community on a non-commercial basis, to improve access to data on the themes of arts, health and new technologies, and to increase knowledge and enable the development of research in these fields.
Study NCT06729372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deliberate Flawed Performance
Description: Deliberate Flawed Performance during simulation-based training
Study NCT06729372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Error Avoidance Training
Description: Error Avoidance during simulation-based training
Study NCT05532735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANXV
Description: ANXV (Human recombinant Annexin A5 protein)
Study NCT04965675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Eptinezumab will be administered per dose and schedule specified in the arm.
Study NCT04965675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to eptinezumab will be administered per schedule specified in the arm.
Study NCT05925257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePRO application and proactive clinical care with nurses.
Description: The investigators defined ePRO intervention as a weekly register of breast cancer patients' symptoms and supportive care needs using the study ePRO App combined with proactive follow-up by nurses guided by predefined clinical algorithms and a weekly cellphone message providing an educational video from a recognised cancer association or health institution. The intervention will be provided for six months with additional three months of post-intervention observation.
Study NCT05574283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block and transmuscular quadratus lumborum block
Description: All blocks were performed after securing the airway before the start of surgery.~ESPB group will receive bilateral ultrasound-guided erector spinae plane block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side.~TQLB group will receive bilateral ultrasound-guided transmuscular quadratus lumborum block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side
Study NCT05646563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 is an anti-Factor Bb humanized monoclonal antibody that will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
Study NCT05646563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soliris
Description: Complement C5 blocker administered intravenously
Study NCT05437640 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protein Redistribution Diet
Description: PD participants will be instructed by a Registered Dietitian to consume 10 grams or less of protein until their evening meal. They will then consume a high protein evening meal to meet their protein needs. They will receive one-on-one education and supportive materials to follow diet plan.
Study NCT05437640 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protein Consistent Diet
Description: PD participants will be instructed by a Registered Dietitian to consume 20-30 grams of protein per meal. They will receive one-on-one education and supportive materials to follow diet plan.
Study NCT04289428 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Xpert® HBV DNA fingerstick point of care assay
Description: Xpert® HBV DNA point of care assay from finger-stick whole blood
Study NCT04403087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimebutine 100 MG
Description: Trimebutine 100mg three times a day
Study NCT04855006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaginal Microbiome Transplant
Description: Vaginal Microbiome Transplant is given at least once and up to three times. The transplant is admitted with a syringe
Study NCT04855006 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal Microbiome Transplant Placebo
Description: Vaginal Microbiome Transplant Placebo is given at least once and up to three times. The transplant Placebo is admitted with a syringe
Study NCT04855006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Donors have no intervention. This group deliver the transplant to arm 'Vaginal Microbiome Transplant'.
Study NCT04854876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-ALA-Phosphate + SFC (5-ALA+SFC)
Description: The food supplement 5-Aminolevulinic acid phosphate and Sodium ferrous citrate (5-ALA-Phosphate + SFC) will be administered orally daily for 28 days. The dose will be in total 3 capsules of 50 mg 5-ALA-Phosphate and 28.68 mg SFC (3.04 mg as Fe) per day, 2 capsules in the morning and 1 capsule in the evening resulting in 150 mg 5-ALA-Phosphate and 86.04 mg SFC ( 9.12 mg as Fe).
Study NCT05486312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-155 smartphone app
Description: The CT-155 study app is designed to provide treatment monitoring and educational components of a full treatment cycle with CT-155. This design allows inferences to be made about the usability and acceptability of CT-155. Eligible participants will be enrolled during an in-person clinic visit on Day 1. Participants will then be directed to access the study app and perform tasks each day for the 49-day engagement period.
Study NCT05996419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DSB-I
Description: Participant will receive text message every other day during active phase (30days) via ANNIE text messaging app related to the safety behaviors they identified prior to start.
Study NCT06395025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insoles
Description: Insoles At Day 0, the patient received the insoles and adapted them to his shoes. The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14. The patient filled a usability's questionnaire at Day14.
Study NCT05039697 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oxygen
Description: deliver high flow oxygen (10L/min)
Study NCT05039697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen
Description: deliver high flow oxygen (10L/min)
Study NCT06612164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kefir
Description: Commercial lactose-free kefir (Altinkilic, Turkey) beverage, which is produced from cow milk with 3.1% fat and 7.5% protein content and stored in appropriate conditions, was used in this study. The kefir (intervention) group was provided with 250 mL of plain lactose-free kefir containing at least 107-1010 probiotic bacterial strains (Lactobacillus, Lactic acid, Streptococcus, Acetic acid bacteria sp) and yeasts (Kluyveromyces marxianus, Torulaspora delbrueckii, Saccharomyces cerevisiae, Candida). The participants were asked to consume 250 mL of plain lactose-free kefir daily for 6 weeks. Any particular time was not specified for kefir consumption. Kefir consumption routine of participants was followed up by regular phone calls every week and evaluated by examining their consumption records. Those who consumed less than 85.0% (skipping kefir consumption maximum once a week) of the planned kefir consumption during the study period were excluded from the study.
Study NCT04035902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Ferric carboxymaltose is administered during surgery
Study NCT04035902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Ferric carboxymaltose is not administered
Study NCT03357419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: The subjects will be randomized, at the operation day, to one of two treatment groups:~* group 1: prophylactic antibiotic~* group 2: placebo oral capsule~  * Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~ * Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses.
Study NCT03357419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The subjects will be randomized, at the operation day, to one of two treatment groups:~* group 1: prophylactic antibiotic~* group 2: placebo~  * Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~ * Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses.
Study NCT04530097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Radiofrequency ablation was performed immediately after enrollment, and melatonin treatment was given for 6 months after 1 week after radiofrequency.
Study NCT06612892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality games in immersive VR modality
Description: virtual reality involved three characters: a muscular boxer, a superhero, and a rock climber, with patients performing tasks in standing or sitting. Each experience takes 6 minutes, with 5-minute intervals between. Experimenters will instruct users on hand controls and virtual body observation.
Study NCT06612892 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality show in passive VR modality:
Description: In this modality the patient was asked to have a comfortable seat wearing the head set without holding the controllers , the therapist will play a relaxing show as a nature view or colorful scene as a sort of relaxation and mind distraction for around 20 minutes while asking the patient to perform upper limb muscle ROM exercise in active or active assisted form.
Study NCT06612892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physiotherapy
Description: Includes stretching exercise for upper limb muscles affected by burn, scar tissue release , and splinting technique.
Study NCT06612892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physiotherapy
Description: Includes stretching exercise for upper limb muscles affected by burn, scar tissue release , and splinting technique.
Study NCT06612775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug CB03-154 5mg group
Description: CB03-154 tablet (5mg/tablet) once daily.
Study NCT06612775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug CB03-154 10mg group
Description: Two CB03-154 tablets (5mg/tablet) once daily.
Study NCT06612775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug CB03-154 20mg group
Description: Four CB03-154 tablets (5mg/tablet) once daily.
Study NCT06612775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Four Placebo tablets once daily.
Study NCT06612632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: research drug in combination with Toripalimab
Description: research drug in combination with Toripalimab
Study NCT06612632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab
Study NCT06380920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI Mindful Eating App
Description: The investigators propose on design of an AI Mindful Eating App, to enhance individual's healthy lifestyle with subsequent weight-loss. Based on gut-brain axis, this is anticipated to be achieved by using CBT, in place of medication, to alleviate food addiction and proper nutrition intake during proper metabolic conditions and time, which are coordinated via AI.
Study NCT06380920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient regular follow-up
Description: Outpatient regular follow-up
Study NCT06380920 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Outpatient regular follow-up
Description: Outpatient regular follow-up
Study NCT06024278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver educational videos for African American caregivers
Description: The intervention will be culturally tailored education videos for African American caregivers receiving hospice services.
Study NCT06024278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver educational videos for Puerto Rican caregivers
Description: The intervention will be culturally tailored education videos for Puerto Rican caregivers receiving hospice services.
Study NCT05956457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Coaching Program
Description: Digital health intervention consisting of weekly calls from a Health Advisor to a participant, accompanied by delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
Study NCT05956457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
Study NCT06520826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: A synthetic, orally bioavailable, small molecule being developed as an inhibitor of hypoxia-inducible factor prolyl-hydroxylases for the treatment of anemia associated with chronic kidney disease. Intervention to be administered to maintain hemoglobin within a target range of 10-11 g/dL.
Study NCT06520826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoiesis Stimulating Agent
Description: Standard of care erythropoiesis stimulating agent will be administered to maintain hemoglobin within a target range of 10-11 g/dL.
Study NCT06370845 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation - Natural Odour
Description: Inhalation of 50 uL of a natural odour via nasal septum mini-inhaler.
Study NCT06370845 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Inhalation - Placebo
Description: Inhalation of 50 uL of Placebo via nasal septum mini-inhaler.
Study NCT05044507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BQ 2.0
Description: frequency and intensity parameters will be set to zero so that no stimulation is delivered
Study NCT05044507 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BQ 2.0
Description: frequency and intensity parameters will be set to zero so that no stimulation is delivered
Study NCT05044507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BQ 2.0
Description: The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
Study NCT05044507 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BQ 2.0
Description: The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
Study NCT04684823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch Cap
Description: A prescription container cap to track the dispensing of an oral dose of medication with an associated app which tracks the adherence to medication regimen.
Study NCT04684823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch App
Description: A mobile app that is used with Patch Cap to track adherence to medication regimen
Study NCT05348941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TECADRIOL
Description: Food supplement containing an association of D-chiro-inositol and alpha-lactalbumin
Study NCT03514329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic Thermal Vapor Ablation
Description: Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power.